Clinical trials: Revascularization
- Condition Revascularization
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Ischemic Stroke
Percutaneous Recanalization in Ischemic Stroke Management in Europe Observational Registry
To determine the revascularization rate, clinical efficacy and safety of the CE-marked MindFrame System in ischemic stroke patients
- Trial name
- PRIISM2 (NCT01560247)
- Testing
- Mechanical thrombectomy
- Volunteers
- 1,000 people
- Sponsor
- MindFrame, Inc.
Stroke, Ischemic Stroke
Gravity Stroke System for Recanalization of Large Vessel Occlusion Strokes
Supernova and Neutron are endovascular mechanical revascularization devices indicated to restore blood flow by removing thrombus from a large intracranial vessel in patients experiencing an acute ischemic stroke within 24 hours…
- Conditions
- Stroke, Ischemic Stroke, Cerebrovascular Disorders, Brain Diseases
- Trial name
- GRASSROOT Reg (NCT07335185)
- Testing
- Supernova revascularization device
- Volunteers
- 3,000 people
- Sponsor
- Gravity Medical Technology, INC
Overall Mortality
Retrospective Follow-up of BIOLUX P-I/-II
The aim is to collect long-term clinical data from 132 patients from Belgium, Germany and Austria who had previously participated in either of the BIOLUX P-I or P-II studies.
- Trial name
- NCT04250909
- Testing
- Passeo-18, Passeo-18 Lux
- Where
- 8 sites in Austria, Belgium and 1 more
- Volunteers
- 132 people
- Sponsor
- Biotronik AG
Peripheral Arterial Occlusive Disease, Chronic Limb-Threatening Ischemia
Safety of Antithrombotic Heparin Proteoglycan Mimetic APAC in Peripheral Arterial Occlusive Disease and Chronic Limb-threatening Ischemia
The goal of this study is to learn if a new medicine (called antiplatelet and anticoagulant [APAC]) can help the body to prevent blood clots and whether APAC is safe and well tolerated in patients with blocked or narrowed…
- Trial name
- HEALING (NCT07352800)
- Testing
- APAC - dose level 0.50 mg/kg,, Unfractionated heparin (UFH), APAC dose level 1: 0.25 mg/kg,
- Where
- 3 sites in Finland
- Volunteers
- 42 people
- Sponsor
- Aplagon Oy